Publications
Original Article
A Phase I/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer
Clinical Trials
2023
Authors:
Disis ML, Dang Y, Coveler AL, Childs JS, Higgins DM, Liu Y, Zhou J, Mackay S, Salazar LG
Journal:
Clinical Cancer Research
Volume:
29(17)
Page:
3362-3371
Pubmed:
Original Article
Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer
Clinical Trials
2022
Authors:
Disis, ML, Guthrie, KA, Liu, Y, Coveler, AL, Higgins, DM, Childs, JS, Dang, Y, and Salazar, LG
Journal:
JAMA Oncology
Volume:
9(1)
Page:
71-78
Pubmed:
Original Article
Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
Clinical Trials
2021
Authors:
John B Liao, William R Gwin, Renata R Urban, Katie M Hitchcock-Bernhardt, Andrew L Coveler, Doreen M Higgins, Jennifer S Childs, Hania N Shakalia, Ron E Swensen, Sasha E Stanton, Anna V Tinker, Tanya A Wahl, Richard G Ancheta, Kathryn F McGonigle, James Y Dai, Mary L Disis, Barbara A Goff
Journal:
Journal for ImmunoTherapy of Cancer
Volume:
9(9)
Page:
Pubmed:
Original Article
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
Clinical Trials
2019
Authors:
Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL.
Journal:
Jama Oncology
Volume:
5(3)
Page:
393-401
Pubmed:
Original Article
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Clinical Trials
2018
Authors:
Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.
Journal:
Clinical Cancer Research
Volume:
24(7)
Page:
1525-1535
Pubmed:
Original Article
Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer
Clinical Trials
2017
Authors:
John B Liao, Ron E Swensen , Kelsie J Ovenell , Katie M Hitchcock-Bernhardt, Jessica L Reichow, Minjun C Apodaca, Leonard D'Amico, Jennifer S Childs, Doreen M Higgins, Barbara J Buening, Barbara A Goff, Mary L Disis
Journal:
Gynecologic Oncology
Volume:
144(3)
Page:
480-485
Pubmed:
Original Article
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation
Clinical Trials
2009
Authors:
Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM.
Journal:
Journal of Clinical Oncology
Volume:
27(35)
Page:
5911-8
Pubmed:
Original Article
Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia
Clinical Trials
2003
Authors:
Ginsburg AS, Salazar LG, True LD and Disis ML
Journal:
American Journal of Hematology
Volume:
72(3)
Page:
204-8
Pubmed:
Review Article
Clinical studies of vaccines targeting breast cancer
Clinical Trials
2003
Authors:
Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG
Journal:
Clinical Cancer Research
Volume:
9(9)
Page:
3222-34
Pubmed:
Original Article
Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor
Clinical Trials
1999
Authors:
McNeel DG, Schiffman K, Disis ML
Journal:
Blood
Volume:
93(8)
Page:
2653-9
Pubmed: